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a b s t r a c t
Introduction: While the neurolupus criteria are well-established, global psychiatric manifes-
tations are of variable frequency in patients with systemic lupus erythematosus (SLE); their 
relation with disease activity is unknown. 
Objective: To evaluate the frequency of psychiatric symptoms in SLE using the Adult Psychi-
atric Morbidity Questionnaire (APMQ); to correlate APMQ changes with disease activity and 
socio-economic variables. 
Materials and methods: This cross-sectional study evaluated patients with active or inactive 
SLE as to the prevalence of psychiatric symptoms utilizing, for the fi rst time, the APMQ. 
Eight or more affi rmative replies out of 45 questions defi ned the APMQ as abnormal. Pa-
tients were classifi ed according to the American Collge of Rheumatology 1997 criteria, and 
disease activity was measured by the SLEDAI. 
Results: Seventy-two SLE patients entered the study, being 68 females (94.4%). Mean age was 
46.1 years (± 12 SD). The frequency of abnormal APMQ was of 89%. Out of the 64 SLE patients 
with altered APMQ, 60 (93.7%) had common mental disorders, mostly anxiety and somati-
zation. There was no correlation of psychiatric symptoms with active disease (rs = 0.09; P = 
0.46), or with history of psychosis and/or seizures attributable to SLE (P = 1.00). Psychiatric 
symptoms also did not correlate with age at disease onset (rs = −0.16) or disease duration 
(rs = −0.11). There was an association of abnormal APMQ with low education level (P = 0.02), 
but not with family income allotted to the patient (P = 0.24). 
Conclusion: The frequency of psychiatric symptoms measured by the APMQ was high in our 
SLE population. An abnormal APMQ was disconnected from SLE activity, but it did associate 
with low education level. 
© 2013 Elsevier Editora Ltda. All rights reserved.
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Sintomas psiquiátricos em pacientes com lúpus eritematoso sistêmico: 
frequência e associação com atividade da doença com o uso do 




Questionário de Morbidade 
Psiquiátrica em Adultos
SLEDAI
r e s u m o
Introdução: Enquanto os critérios de neurolúpus estão bem-estabelecidos, manifestações 
psiquiátricas globais são de frequência variável em pacientes com lúpus eritematoso sistê-
mico (LES); suas relações com atividade da doença e prognóstico são desconhecidas.
Objetivo: Avaliar a frequência de sintomas psiquiátricos no LES utilizando o Questionário de 
Morbidade Psiquiátrica em Adultos (QMPA); correlacionar alterações no QMPA com ativida-
de da doença e variáveis socioeconômicas. 
Materiais e métodos: Este estudo transversal avaliou pacientes com LES ativo ou inativo 
quanto à prevalência de sintomas psiquiátricos utilizando, pela primeira vez, o QMPA. Oito 
ou mais respostas afi rmativas entre 45 perguntas defi niram um QMPA como anormal. Os 
pacientes foram classifi cados de acordo com os critérios de 1997, e o grau de atividade da 
doença foi mensurado pelo SLEDAI. 
Resultados: Participaram do estudo 72 pacientes com LES, dos quais 68 eram do sexo femini-
no (94,4%). A média de idade foi de 46,1 anos (± 12 DP). A frequência de QMPA anormal foi de 
89%. Entre os 64 pacientes lúpicos com QMPA alterado, 60 (93,7%) apresentavam distúrbios 
mentais comuns, a maioria ansiedade e somatização. Não houve correlação de sintomas 
psiquiátricos com atividade da doença (P = 0,46; rs = 0,09) ou com história de psicose e/ou 
convulsões atribuíveis ao LES (P = 1,00). Sintomas psiquiátricos também não se correlacio-
naram com idade de início da doença (rs = −0,16) ou duração da doença (rs = −0,11). Houve 
associação de QMPA anormal com baixo nível educacional (P=0,02), mas não com renda 
familiar destinada ao paciente (P = 0,24).
Conclusão: A frequência de sintomas psiquiátricos medidos pelo QMPA foi alta em nossa 
população com LES. Um QMPA anormal esteve dissociado da atividade do LES, mas se asso-
ciou com baixo nível educacional.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction
Systemic lupus erythematosus (SLE) is a chronic multisys-
temic disorder of unpredictable outcome. Genetic, hormonal, 
and environmental factors are involved in its etiology. The in-
fl uence of psychological factors on activity and outcome of 
disease is a matter to be considered.1 
Seizures and psychosis are classical criteria for neuropsy-
chiatric SLE, occurring in up to 20% of cases.2 Overall, neu-
ropsychiatric manifestations of SLE are seen in 9 to 80% of 
cases.3 Headache is the most frequent neurological manifes-
tation, and stroke the most severe.4 Anti-neuronal antibod-
ies,5 as well as antibodies to receptors NR2,6 have been recent-
ly associated to brain involvement in SLE patients. Apart from 
vasculitis, complex neuropsychiatric syndromes in SLE may 
also be the result of ischemia, early atherosclerosis or associ-
ated morbidities.7
While the organic neuropsychiatric syndromes are well 
known in SLE patients, the global frequency of psychiatric 
symptoms in these patients has been a polemic issue. Fa-
tigue, fi bromyalgia, cognitive dysfunction and depression are 
all contributors to poor quality of life in SLE patients. These 
disturbs comprise notorious bias for psychological assess-
ment of these patients.7 A variety of instruments have been 
developed to measure health-related quality of life in SLE; 
among them, the Medical Outcomes Survey Short Form 36 
has been the most common method utilized in these group 
of patients.8 
The psychometric assessment of SLE patients can be ob-
tained by using the Wechsler scale7 and the cognitive symp-
toms inventory.9,10 Common mental disorders (CMD, here 
comprising depressive, anxiety and somatoforms disturbs) 
can, in turn, be evaluated by the DSM-IV (Diagnostic and Sta-
tistical Manual of Mental Disorders, Fourth Edition),11 but also 
by depression, anxiety and/or stress scales,12 socioeconomic 
scales13 and personality scales.14 There is no consensual 
method to evaluate psychiatric symptoms in SLE, and such 
multiplicity of approaches turn problematic the comprehen-
sion of the psychiatric morbidity of such patients. 
The Adult Psychiatric Morbidity Questionnaire (APMQ), 
described in 1982,15 is an instrument structured in factors, 
aiming to characterize symptoms of CMD or psychosis. Even 
though each APMQ factor is not diagnostic on its own, it might 
represent a psychopatological dimension potentially useful in 
the screening of psychiatric disorders. 
To date, the APMQ has not been utilized in the screening 
of psychiatric morbidity in patients with chronic autoimmune 
disease. In the current study, we aimed to utilize the APMQ in 
the evaluation of psychiatric symptoms of patients with SLE. 
In parallel, we sought to investigate the correlation of APMQ 
scores with disease activity, history of psychosis and/or sei-
zures attributable to SLE, age at disease onset, disease dura-
tion, education level, and family income allotted to the patient. 
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Materials and methods
Subjects 
This cross-sectional study included SLE patients followed 
in the Outpatient Unit (Lupus Clinic) of our Rheumatology 
Department, Hospital São Lucas, of Pontífi ca Universidade 
Católica do Rio Grande do Sul (PUCRS). We recruited consecu-
tive subjects during the last two years. The inclusion criteria 
were: a) patients 15 years of age or older, of both sexes, who 
agreed to enter the study; b) patients with at least 4 of the 
11 ACR 1997 criteria for classifi cation of SLE.16 Patients with 
clinical or laboratory data insuffi cient to allow evaluation of 
disease activity were excluded.
SLE patients answered the psychiatric questionnaire and 
responded to a structured interview concerning their demo-
graphic background. All patients authorized the use of their 
medical chart to determine de grade of disease activity (sys-
temic lupus erythematosus disease activity index, SLEDAI). 
All participants signed an informed consent form. The study 
was approved by the Ethics Committee of the Hospital São 
Lucas of PUCRS (CEP/PUCRS 08/04469).
Measures
Demographic and clinical data of the SLE patients were ob-
tained by interview and searching of their medical records. 
The demographic variables included age, sex, race, socioeco-
nomic status, and education level. 
The psychiatric symptoms were evaluated using the 45-
item APMQ.17 The scale groups symptoms in factors to dis-
tinguish individuals with features of anxiety/somatization or 
irritability/ depression (CMD) from those with psychosis, the 
latter characterized by delirium, paranoid features and audi-
tive hallucination. The alternatives for answers were “yes” or 
“no”, to which were attributed values of 1 or 0, respectively. 
The fi rst 43 questions regarded to symptoms proper of the 
individual being interviewed, whereas the last 2 questions (44 
and 45) related to symptoms which might be present in any 
member of the family. 
The 45 questions included in the APMQ were carried out 
as follows: 
Since last year…
1. Have you suffered from lack of appetite? 
2. Have you had diffi culty to sleep? 
3. Have you suffered from buzzing in your ears or mental 
agony? 
4. Have you experimented stabbing pain in your head or 
headaches? 
5. Have you noticed weakness in your legs, or nerve pain? 
6. Have you become aggressive, “exploding” easily? 
7. Have you felt depressed, or demotivated? 
8. Have you felt a lump in the throat, burning or fullness 
in the stomach? 
9. Have you experienced trembling or coldness in your hands? 
10. Have you often had bouts of irritability? 
11. Have you been having diffi culties on understanding, 
learning or remembering? 
12. Have you been consuming alcoholic beverages? 
13. Have you ever got stuck crying a lot? 
14. Have you considered committing suicide? 
15. Have you noticed you were out of control, affected by 
mental illness? 
16. Have you been unable to work due to nervousness or 
mental illness? 
17. Have you ever felt that you could not speak or see prop-
erly? 
18.  Have you ever locked yourself in your room to avoid 
seeing anyone? 
19. Have you got drunk at least once a week? 
20. Do you drink every day? 
21. Have you experimented heart palpitation or tightness? 
22. Have you suffered from anxiety? 
23. Have you been concerned about being ill? 
24. Have you had an attack after being scared or upset? 
25. Have you been afraid of things, animals, darkness or 
closed places? 
26. Have you ever had to ensure that the doors were closed 
after you had closed them? 
27. Have you been hearing voices or seeing things others 
do not see? 
28. Have you ever been told that you say things which do 
not make sense? 
29. Have you been speaking or laughing alone? 
30. Have you ever felt that you have been followed? Have 
you ever noticed that people wish you bad luck? 
31. Have you ever felt telepathically controlled by radio or 
by spirit? 
32. Have you ever stayed a long time in an awkward position? 
33. Have you had moments when you feel very happy 
without any reason? 
34. Have you been moving, singing or talking non-stop? 
35. Have you taken medicines to sleep or to get calm? 
36. Have you ever felt that you could not attend school? 
37. Have you suffered from bouts of madness? 
38. Have you suffered from mental retardation? 
39. Have you been concerned about cleaning in an exag-
gerated way? 
40. Have you been treated for anxiety or mental illness? 
41. Have you presented seizures falling to the fl oor with 
muscular contractions? 
42. Have you been using drugs? Which one? 
43. Have you consumed alcohol excessively? 
Someone in your family… 
44. Does not know how to get dressed? Urinates or def-
ecates in their own clothes? 
45. Does not speak, does not walk or does not recognize 
people?
In the screening for psychopaties, APMQ questions as 
those of numbers 3, 4, 5, 7, 8, 9 and 21 group symptoms more 
properly related to the anxiety/somatization factor; in turn, 
the questions 6, 7, 10, 13, 14 and 18 congregate symptoms 
more linked to the irritability/depression factor. The ques-
tions 27, 30 and 31 assemble symptoms pertinent to psychotic 
disturbs. 
The APMQ was considered positive for the presence of 
psychiatric symptoms if the patient scored 8 or more affi r-
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mative answers.17 The questionnaire was applied by the fi rst 
author and by two trained psychologists.
Disease activity was evaluated by the SLEDAI; 24 clinical 
variables were studied. The “weighted” index of 9 organ sys-
tems for disease activity were utilized as follows: 8 for central 
nervous system and vascular system, 4 for renal and muscu-
loskeletal, 2 for serosal, dermal and immunological, and 1 for 
constitutional and hematological features. An SLEDAI above 4 
was compatible with active disease.18 The clinical and labora-
torial data to calculate the SLEDAI score were obtained within 
10 days, at the most, from the APMQ evaluation. 
The following variables were also correlated with the 
APMQ scores: previous history of psychosis and/or seizures 
attributable to SLE according to medical records; age at dis-
ease onset; disease duration; education level (being low edu-
cation level up to elementary school, and high education level 
the high school or college); and family income allotted to the 
patient (in Brazilian minimum salaries). 
Data analysis 
Quantitative statistical analysis was performed using a SPSS 
13.0 software, considering a 5% level of signifi cance. The vari-
ables were described by means and standard deviation or 
by absolute and relative frequencies. The statistical analysis 
included Student’s t test and the Mann-Whitney test for the 
continuous variables, and chi-square or Fisher’s exact test for 
categorical variables. Spearman’s test was utilized to calcu-
late the correlation coeffi cient.
Results
The fi nal sample consisted of 72 SLE patients, 68 (94.4%) fe-
males and 60 (83.3%) of the white ethnicity. The mean age was 
46.1 years (SD ± 12). The mean age at disease onset was 35 
years, and the mean duration of disease was 13 years. Ap-
proximately half of the patients had the disease for 10 years 
or less; one-third had less than 5 years of disease duration. 
Regarding the educational level, 47 patients (65.2%) did not 
reach the high school level. In 80.5% of the cases, the family 
income allotted to the patient was 1.5 times or less the Brazil-
ian minimum salary. Nearly all (96%) patients were utilizing 
corticosteroids. Table 1 presents the demographic and clinical 
characteristics of our patients with SLE.
The overall prevalence of abnormal APMQ scores was 89% 
in our SLE population (64 patients). Sixty of the 64 SLE pa-
tients (93.7%) with psychiatric symptoms could be classifi ed 
as having CMD and 4 (6.3%) as having psychosis. Among the 
60 patients with CMD, 50 (83.3%) had anxiety/somatization 
symptoms, while 10 patients (16.7%) showed irritability/de-
pression.
Out of the total number of patients with SLE, 27 (37.5%) 
showed active disease (SLEDAI ≥ 4). Table 2 shows the rela-
tionship of APMQ scores with SLE activity measured by the 
SLEDAI. Psychiatric symptoms did not associate with elevated 
scores of SLEDAI.
Fig. 1 presents the graphical distribution of patients ac-
cording to the scores reached in the APMQ and SLEDAI, con-
sidering quantitative variables and the Spearman coeffi cient 
of correlation (rs). There was no signifi cant correlation of 
APMQ scores with the SLEDAI. A straight line could not be es-
timated, once the rs was lower than 0.5. 
Among the 72 SLE patients, 12 (16.6%) had past history of 
psychosis and/or seizures attributable to disease. There was 
no association of elevated APMQ scores with this variable (P 
= 1.00, Fisher’s test). Psychiatric symptoms also did not cor-
relate with age at disease onset (rs = −0.16; P = 0.2) or disease 
duration (rs = −0.11; P = 0.3).
The association of psychiatric symptoms with educational 
level and family income allotted to the patient is presented in 
Table 3. There was a signifi cant association of elevated APMQ 
scores with low educational level, but not with family income 
allotted to the patient.
Discussion
The APMQ is a screening instrument for psychiatric morbid-
ity described nearly three decades behind.15,19 The interdepen-
dency of variables and the psychometric properties of APMQ, 
Table 1 – Demographic and clinical characteristics of 
patients with systemic lupus erythematosus.
Characteristics Total (n = 72)
Females 68 (94.4%)
White ethnicity 60 (83.3%)
Mean age 46.1 (SD ± 12)  
Age at disease onset (years)
Before 20 8 (11.1%)
From 21 to 40 47 (65.3%)
Over 40 17 (23.6%)
Disease duration (years)
Up to 5 23 (32%)
From 6 to 10 17 (24%)
From 11 to 15 10 (14%)
From 16 to 20 11 (15%)
From 21 to 25 2 (3%%)
Over 25 9 (12%)
Education levela
Low education level 47 (65.2%)
High education level 25 (34.7%)
Family income allotted to the patient (times minimum salary)
Up to 1.5 58 (80.5%)
From 1.6 to 3 10 (14%)
From 3.1 to 4.5 4 (5.5%)
n, sample number;  SD, standard deviation.
a Low education level: up to elementary school; high education 
level, high school or college.
Table 2 – Association of the Adult Psychiatric 
Morbidity Questionnaire scores with systemic lupus 
erythematosus activity scores.





High SLEDAI (n = 27) 25 (92.6%) 2 (7.4%) 0.23
Normal SLEDAI (n = 45) 39 (86.7%) 6 (13.3%)
n, sample number; High APMQ, adult psychiatric morbidity 
questionnaire score ≥ 8; a chi-square test; High SLEDAI, systemic 
lupus erythematosus disease activity index ≥ 4.
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determined by multivariate analysis, indicated that the ques-
tionnaire factors were consonant with the respective psy-
chopathies (CMD, psychosis) defi ned in clinical practice.15,17,19 
In populational inquiries using a cut-point of 6/7, the method 
showed good sensitivity (75% to 93%), variable specifi city (be-
tween 53% and 94%) and a kappa of 0.88.15,17,19 
Over the last years, the scale was utilized in a quite large 
context: to study the relationship of the parents’ mental 
health with the mental health of children;19 to assess the ef-
fect of socioeconomic variables and family milieu on child 
mental health;20 to evaluate the epidemiology of psychotropic 
use in the city of São Paulo;21 to assess mental health of the 
mothers of malnourished children;22 to evaluate the impact 
of informal jobs in the mental health of women;23 to verify 
the effect of housework and paid work on psychiatric symp-
toms;24 to evaluate depressive and anxiety symptoms among 
housemaids; 25 to assess the effects of social inequality in the 
prevalence of depressive disorders in Bahia, Brazil;26 and to 
screen psychiatric morbidity in pregnant women on alcohol 
use.27  The present study utilizes for the fi rst time the APMQ 
in the verifi cation of psychiatric symptoms in SLE patients.
Our SLE patients were predominantly females (94.4%) and 
of the white ethnicity (83.3%), with a mean age of 46.1 years. 
The literature points to a higher SLE incidence in non-white 
women aged 20 to 30 years.28 Our demographic data showed 
similarity with the literature regarding sex predominance, but 
differed regarding to race.28 In accordance with our fi ndings, 
Chahade et al. documented a high incidence of SLE in Cauca-
sians of the Brazilian Southeast.29
Approximately two-thirds of our SLE survey had a disease 
onset at 20 to 40 years of age, fi ndings suportted by the Ameri-
can literature.30 About one-third had less than 5 years of dis-
ease duration. Our SLE sample, largely dependent on public 
health services, had, in general terms, a low educational level: 
65.2% of the patients did not attend high school. In 80.5% of 
cases, the family income allotted to the patient was 1.5 times 
the minimum salary or less. For short, this survey is represen-
tative of a public tertiary center of a big Southern city (mostly 
white, low income, low education level). 
The frequency of psychiatric symptoms evaluated by the 
APMQ was very high in our SLE population (89%). Of inter-
est, the prevalence of psychiatric disturbs as screened by the 
APMQ was previously assessed in 6746 individuals of three 
metropolitans areas of Brazil (Brasília, São Paulo and Porto 
Alegre). The frequency of psychopathology (mostly anxiety 
disorders) ranged from 19% (São Paulo) to 34% (Brasília and 
Porto Alegre). That report31 comprised the fi rst Brazilian in-
vestigation of mental ilness in an urban population, and 
brought about our interest for screening psychiatric illness 
in SLE using the APMQ. As seen, the prevalence of an abnor-
mal APMQ largely differed when a sample of general popula-
tion31 is compared, even indirectly, to a specifi c group of SLE 
patients. 
The 89% prevalence of abnormal APMQ in our SLE patients 
may well be an overestimate. The test might be hypersensi-
tive by detecting symptoms of functional syndromes (ques-
tions 2, 4, 9 and 21, for instance) or organic complaints of SLE 
(questions 1, 41). In a hospital-based study including thirty 
patients, the prevalence of psychiatric disorders using anoth-
er method (the Presumptive Stressful Life Event Scale) was of 
50%, according to a study from 1999.32 In a Brazilian survey of 
SLE patients evaluated by traditional scales, cognitive disor-
ders, anxiety and/or depression were seen in 75% of the cases, 
a frequency close to ours regarding CMD.33 
Among our 64 SLE patients with psychiatric symptoms, 
there was a strong predominance of CMD (93.7%) in compari-
son to psychosis (6.3%). Inside the CMD picture, most of the 
patients (83.3%) fi t in the anxiety/somatization group, and the 
remaining in the irritability/depression category. In the large 
group of patients with the anxiety/somatization factor, symp-
toms attributable to SLE such fatigue and “leg weakness”34 
were also computed in our study (question 5 of APMQ); this 
overlapping of psychiatric and organic symptoms may have 
generated a confounding bias in our analysis. 
Our data did not point to a signifi cant correlation of APMQ 
scores with disease activity measured by the SLEDAI. Out of 
Table 3 – Association of psychiatric symptoms with 










High education level 19 (76%) 6 (24%) 0.02a
Low education level 45 (96%) 2 (4%)
Family income allotted to the patient




Positive APMQ, adult psychiatric morbidity questionnaire score ≥ 
8; n, sample number; High education level, high school or college; 
Low education level, up to elementary school.
a Chi-square test.
















0,00 5,00 10,00 15,00 20,00 25,00 30,00
Fig. 1 – Distribution of patients according to the scores of 
adult psychiatric morbidity questionnaire (APMQ) and of 
the systemic lupus erythematosus disease activity index 
(SLEDAI). 
rs, Spearman coeffi cient of correlation; P, Student’s t test.
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83 Chilean patients with SLE evaluated for psychiatric mor-
bidity by the DSM-IV and a psychological suffering scale, 
44.6% presented psychiatric diagnoses, particularly major de-
pressive episodes. In accordance with our study, there was no 
correlation of psychiatric distress with disease activity.35
Three studies, also using other methods but not the 
QMPA, corroborated a lack of association between psychi-
atric illness and disease activity.32,33,36 This fi nding suggests 
that the psychological suffering of these patients, mani-
fested mainly by CMD, could have a multifactorial etiology, 
including disease chronicity, treatment and socioeconomic 
variables.32,33,36 Some Brazilian studies, in fact, accounted 
for worsening of SLE symptoms due to psychological fac-
tors.37-39 According to Toloza et al, the current measures to 
appraise disease activity and organic damage in SLE do not 
seem “to capture” the health-related quality of life of such 
patients.40 
Of major interest, we also did not observe an association of 
altered APMQ with previous history of psychosis and/or sei-
zures, classical psychiatric SLE criteria.2,41 We could then in-
fer that the psychiatric symptoms currently extracted by the 
APMQ are not in a direct way linked to history of neurolupus. 
The literature indicates that the earlier the onset of SLE, 
the more serious the clinical features can be.42 Although ele-
vated APMQ scores would be expected to be more frequent in 
patients early disease, this correlation was not confi rmed in 
our study. Considering previous reports claiming cumulative 
brain damage in patients with SLE,43 an association of psychi-
atric symptoms with longer disease duration would be plau-
sible, but this correlation was also not evident in our survey.
A correlation of psychiatric symptoms with low educa-
tional level (below high school) was noticed in our SLE sur-
vey. In another words, SLE patients with higher educational 
level could be less susceptible to affi rmative answers in the 
APMQ. It is possible, also, that individuals with lower educa-
tion level have had more diffi culty in leading with the exten-
sion and complexity of the questionnaire, resulting in a bias 
of positive answers. 
Eleven Brazilian patients with SLE were recently evaluat-
ed for neuropsychological function using the “mini-mental”, 
neuropsychiatric inventory and other tests. A defi ned impair-
ment of cognitive functions was documented, and these al-
terations also related to a low education level. Worthy of note, 
symptoms of anxiety/irritability and hallucinations were par-
ticularly frequent in these individuals.44 
Our data did not confi rm a correlation of abnormal APMQ 
with family income allotted to the patient. According to a re-
cent report, chronic disease, low educational level and low 
acquisitive power predisposed to depressive, anxiety and so-
matoform disturbances in SLE.45 These discrepancies on the 
role of acquisitive power on psychiatric disturbs of SLE pa-
tients shall be clarifi ed in forecoming studies.
Although deprived from diagnostic properties, the APMQ, 
with its wide structure in factors, seemed useful in the screen-
ing of CMD (which largely predominated in our SLE sample), 
as well as in the differentiation of CMD with psychosis. In pa-
tients with altered APMQ, more specifi c psychiatric diagnoses 
can potentially be obtained in a future longitudinal study.
Our study shows limitations which must be mentioned, 
the uncontrolled cross-sectional design being the fi rst of 
them. The absence of a control group without SLE restricted 
the statistical analysis. The low number of individuals with 
psychosis did not allow analysis of subgroups of patients 
with abnormal APMQ. Also, a majority of our patients (96%) 
were using corticosteroids, so that it was not statistically 
feasible to associate psychiatric symptoms with the intake 
of these drugs. 
Knowingly, corticosteroid intake is linked to disturbances 
of sleep, cognition and behaviour.46 Stratifi cation for cortico-
steroid dosage could have been performed in our study, once 
dose is related to incidence of psychiatric symptoms; nev-
ertheless, dosage does not appear to associate to severity or 
duration of psychiatric features.46 Our SLE patients were not 
subdivided as to use of psychotropics, also due to the high 
frequency of intake of such drugs; besides, a large variety of 
psychotropics were utilized by different patients, turning dif-
fi cult the stratifi cation. The fact that we have evaluated a spe-
cifi c SLE population of tertiary center (as a whole with low 
education level and low income) also restrict our results. As 
a limitation of APMQ per si, the method evaluated symptoms 
present only in the last year. 
In summary, an abnormal APMQ was highly frequent 
in SLE patients. The test might be hypersensitive; anyhow, 
these data bring into discussion the need for more aggressive 
screening programs of psychological disturbs in SLE popula-
tions. An abnormal APMQ did not correlate with active dis-
ease, and the association of an altered test with low educa-
tion level requires elucidation. Further studies are warranted 
to confi rm the usefulness of the APMQ as screening instru-
ment for psychiatric morbidity in SLE patients.
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